Univercells Technologies by Donaldson introduces the scale-X nexo bioreactor – offering a 0.5 m² growth surface, designed for efficient cell culture process development across multiple modalities.
Read article "Univercells Technologies by Donaldson launches the scale-X™ nexo mini bioreactor for cost-efficient, scalable cell culture process development across modalities"Corporate
GTP, renowned for its pioneering work in gene therapy, seeks to make gene therapies for rare diseases accessible worldwide.
Read article "Donaldson Company, Inc., through its Univercells Technologies business, expands their relationship with the Gene Therapy Program at the University of Pennsylvania to evaluate certain bioreactors for scalable gene therapy production"
The first phase will focus on lentivirus (LV) manufacturing, concentrating on improving recoveries with a scalable process while keeping the manufacturing footprint small.
Read article "Donaldson Announces Integrated Lentiviral Vector Manufacturing Platform Development"
Utilizing the scale-X™ hydro system, BIONET aims to enhance the production of extracellular vesicles produced by Mesenchymal Stem Cells (MSCs) for clinical use. This development is a notable advancement in the mass production of standardized cell and gene therapies.
Read article "BIONET and Univercells Technologies’ collaboration propels mass production of exosomes with scale-X™ bioreactor integration"
MINNEAPOLIS (June 29, 2023) — Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, today announced the acquisition of Univercells Technologies, a global producer […]
Read article "Donaldson Acquires Univercells Technologies, Broadens Life Sciences Reach"
Obio will leverage the NevoLine™ Upstream biomanufacturing platform with scale-X™ bioreactors of Univercells Technologies in OBiO’s recently expanded GMP facility in Shangai to accelerate gene therapy manufacturing.
Read article "OBiO Technology adds scale-X™ and NevoLine™ Upstream platforms to accelerate gene therapy manufacturing in Shanghai"
Univercells Technologies has completed a EUR 2 m expansion of the Nivelles, Belgium site. The critical investment was made to deliver a deeper level of support and supply chain security to biomanufacturers.
Read article "Univercells Technologies completes Nivelles facility expansion, tripling manufacturing and R&D capacity"
The scale-X™ cell collect module has been designed to overcome these challenges, resulting in a reduced aseptic risk, and a decrease in costs, footprint, and operational time, coupled with high reproducibility.
Read article "New benchtop seed train system overcomes bottlenecks of advanced therapy large-scale manufacture"
In this newly created role, Ms. Vicaire will be responsible for the commercialization and continued expansion of the company’s enabling portfolio of biomanufacturing technologies and services.
Read article "Florence Vicaire joins Univercells Technologies as CCO"
TFBS will leverage the scale-X™ carbo mid-scale fixed-bed bioreactor from Univercells Technologies for good manufacturing practice (GMP) viral vector operations at the expanding state-of-the-art Taipei facility.
Read article "TFBS Biosciences, Inc. Partners with Univercells Technologies to Develop GMP Mid-Scale Processes Using the scale-X™ carbo Bioreactor"
CBET becomes first US-based training partner for Univercells Technologies; partnership provides opportunities to prepare ACPHS students for successful careers in cell and gene therapy.
Read article "Albany College of Pharmacy and Health Sciences’ (ACPHS) Stack Family Center for Biopharmaceutical Education and Training (CBET) partners with Belgian-based Univercells Technologies to support bioproduction advances"
Partnership will optimize manufacturing of extracellular vesicles (EVs) using scalable and continuous bioprocessing technologies to propel the commercialization of regenerative therapies at affordable costs.
Read article "Partnership with RoosterBio to advance scalable & continuous exosomes manufacture"
The two companies announce a worldwide strategic partnership to develop and optimize platform processes using best-in-class technologies for the production of custom viral vectors.
Read article "New strategic partnership with VectorBuilder for optimized custom viral vector production"
The scale-X carbo will be featured at the Dublin facility for biopharma industry researchers and personnel to gain hands-on experience with this and other leading next-generation, enabling biomanufacturing technologies
Read article "NIBRT adds scale-X™ carbo system for upstream viral manufacturing demonstrations and training"
In his new role, Mathias will take the company through the next stage of strategic development and growth
Read article "Mathias Garny appointed as CEO of Univercells Technologies"
Exyte and Univercells Technologies are announcing a global partnership for optimized construction of modular standardized and flexible GMP manufacturing facilities for vaccines.
Read article "New partnership with Exyte for rapid deployment of vaccine production plants in the wake of the COVID-19 pandemic"
Univercells Technologies, a global provider of next-generation bioprocess technologies, launches today. Under this new brand, the company will focus on the commercialization of the product portfolio and will explore new technology developments […]
Read article "Launch of Univercells Technologies for intensified, automated technologies"
The investment will be deployed in a newly created subsidiary of Univercells focused on accelerating the industrialization and commercialization of Univercells’ manufacturing technologies
Read article "€50M investment from KKR platform to accelerate the commercialization of technologies portfolio"
Inauguration of new facility for the development and production of our technology solutions in Nivelles, Belgium
Read article "Inauguration of our new Equipment Design Center"
Univercells Receives $12 Million Grant to Develop Breakthrough Vaccine Manufacturing Platform
Read article "$12 million grant to develop breakthrough vaccine manufacturing platform"